

primary studies - published RCT

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

Code: PM16236892

Year: 2005 **Date:** 2005

Author: Blumer JL

Study design (if review, criteria of inclusion for studies)

blinded RCT.

Participants

Patients who were $>$ or $=$ 5 years of age who were infected with ceftazidime-susceptible *Pseudomonas aeruginosa* were stratified by lung function and randomized to treatment with meropenem/tobramycin or ceftazidime/tobramycin. Patients infected with *Burkholderia cepacia* complex or ceftazidime-resistant *P. aeruginosa* were assigned to receive open-label meropenem/tobramycin. 102 CF patients

Interventions

IV meropenem (40 mg/kg to 2 g q8h) or ceftazidime (5 mg/kg to 2 g q8h), each of which was administered with IV tobramycin (at a serum peak of $>$ or $=$ 8 microg/mL and a trough of

Outcome measures

Clinical response was assessed by spirometry to determine the change in percent predicted FEV1 and by a clinical acute change score (ACS)

Main results

patients were randomized to meropenem/tobramycin ($n = 50$) or ceftazidime/tobramycin ($n = 52$). Nineteen patients received open-label meropenem/tobramycin. FEV1 was improved at the end of treatment (EOT) with meropenem/tobramycin (mean \pm SD] increase, 38.8 \pm 52.3%) and with ceftazidime/tobramycin (mean increase, 29.4 \pm 35.1%; $p < 0.0001$ vs baseline values). The proportion of patients with $>$ or $=$ 15% relative increase from baseline FEV1 (satisfactory response) at day 7 was 62% for the meropenem/tobramycin group and 44% for the ceftazidime/tobramycin group ($p = 0.04$). The median time to FEV1 response was 4 days for meropenem/tobramycin therapy vs 6 days for ceftazidime/tobramycin therapy. Similarly, FEV1 improved in the open-label group (mean increase, 12.5 \pm 25.7%; $p = 0.05$). ACS improved in all three groups at EOT (p

Authors' conclusions

Therapy with both meropenem/tobramycin and ceftazidime/tobramycin improved pulmonary and clinical status and reduced sputum bacterial burden in CF patients with APEs. A larger proportion of patients receiving meropenem/tobramycin therapy demonstrated a satisfactory FEV1 response at day 7. Resistant *P. aeruginosa* emerged infrequently during treatment with both regimens.

<http://dx.doi.org/10.1378/chest.128.4.2336>

See also

Chest. 2005 Oct;128(4):2336-46.

Keywords

Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; *Burkholderia cepacia*; Ceftazidime; Child; Combined Modality Therapy; Infection; Meropenem; pharmacological_intervention; *Pseudomonas aeruginosa*; *Pseudomonas*; Respiratory Tract Diseases; Respiratory Tract Infections; Thienamycin; Tobramycin; Exacerbation; Cephalosporins; Carbapenems; Aminoglycosides;